Clinical trials: Hair Problems
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study.
- Trial name
- AA (NCT05255237)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Alopecia Areata
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.
- Trial name
- NCT04034134
- Testing
- Jaktinib Hydrochloride Tablets
- Where
- 2 sites in China
- Volunteers
- 111 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Port Wine Stain, Nevus of Ota
Optical Clearing of the Skin in Conjunction With Laser Treatments
The research hypothesis is that topical application of a mixture of pre-polymers of polypropylene glycol and polyethylene glycol (an optical clearing agent) will reduce skin light scattering, increasing the amount of light…
- Conditions
- Port Wine Stain, Nevus of Ota, Tattoos, Scars
- Trial name
- NCT00580736
- Testing
- Optical Clearing
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Androgenic Alopecia
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
To compare the outcome of topical minoxidil 5% spray versus oral minoxidil 2.5 mg tablet for the treatment of androgenetic alopecia in males and females.
- Trial name
- mina (NCT07273799)
- Testing
- Minoxidil 5 % Topical Spray, minoxidil
- Volunteers
- 200 people
- Sponsor
- Sheikh Zayed Federal Postgraduate Medical Institute
Androgenic Alopecia
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia
- Trial name
- NCT06326359
- Testing
- autologous stromal vascular fraction
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sohag University
Thin Hair, Hair Loss
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth by applying a serum daily on the scalp of men and women with thinning hair. The main aims of this trial are: 1.
- Conditions
- Thin Hair, Hair Loss, Alopecia, Thinning Hair
- Trial name
- NCT07228156
- Testing
- Xtresse Serum
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study
Alopecia areata (AA) is a common autoimmune disease that targets hair follicles with a prevalence of approximately 0.1% and a lifetime incidence of approximately 1.7%. AA is the third most prevalent nonscarring hair loss disease.
- Trial name
- NCT05502952
- Testing
- Pentoxifylline
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Central Centrifugal Cicatricial Alopecia
Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia
This study aims to investigate whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that mostly affects women of African descent.
- Trial name
- NCT06998433
- Testing
- Platelet-Rich Plasma (PRP) Injections, Saline
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Baylor College of Medicine
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451021
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Autoimmune Diseases, Inflammatory Disease
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system.
- Conditions
- Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia, Systemic Lupus Erythematosus
- Trial name
- MuTreg (NCT05544448)
- Testing
- Blood sample taken at a single time point
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alopecia
LLLT for Alopecia of the Eyebrow in Women
The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system…
- Trial name
- NCT04897555
- Testing
- LLLT
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Alopecia
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido.
- Trial name
- NCT02014584
- Testing
- Dutasteride
- Where
- 18 sites in Chile, Hong Kong and 3 more
- Volunteers
- 117 people
- Sponsor
- Stiefel, a GSK Company
Alopecia Areata
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
Alopecia areata (AA) in the acute phase with active hair shedding causes significant psychological distress, prompting the need for effective treatment.
- Trial name
- MQ7422 (NCT06797310)
- Testing
- Baricitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Androgenic Alopecia
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical…
- Trial name
- NCT07502976
- Testing
- Topical 2-Deoxy-D-ribose Hydrogel, Topical Minoxidil 5% Solution
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Phase II clinical trial
- Trial name
- ELAN (NCT02919735)
- Testing
- CG 428 cutaneous solution
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Legacy Healthcare SA
Alopecia Areata
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
- Trial name
- NCT00484679
- Testing
- Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Minnesota